Roche is trading at $61.43, up 3.04%, after Deutsche Bank’s upgrade to Buy, citing positive physician feedback on its cancer drug giredestrant. - On October 23, Deutsche Bank upgraded Roche from Hold and raised its target to CHF 500 from CHF 340. - Third-quarter sales beat expectations, but shares initially slipped and Roche kept its full-year outlook unchanged. - Healthcare fell 1.29%; the sector trend does not explain the gain. Cited coverage did not establish trading-volume details.